| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
1.29(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.58 - $25.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
| Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
| Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
9 |
12 |
17 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yao Tony Dung Ling |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$502,466 |
I/I |
155,966 |
4,450 |
|
- |
|
| Yao Tony Dung Ling |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,450 |
4,450 |
|
- |
|
| Schinazi Raymond F |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$502,466 |
I/I |
93,048 |
93,048 |
|
- |
|
| Goodman Corey S |
10% Owner |
– – • |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
4,215,141 |
4,265,141 |
|
- |
|
| Goodman Corey S |
10% Owner |
– – • |
2019-04-01 |
4 |
B |
$16.00 |
$800,000 |
I/I |
50,000 |
50,000 |
1.5 |
- |
|
| Smith J. Jefferson |
10% Owner |
– – • |
2019-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,845,170 |
|
- |
|
| Jantz Derek |
Chief Scientific OfficerOffice |
• • • |
2019-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,845,170 |
|
- |
|
| Kane Matthew R. |
President and CEOOfficer |
• • • |
2019-03-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,067 |
|
- |
|
| Kane Matthew R. |
President and CEOOfficer |
• • • |
2019-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,802,427 |
|
- |
|
159 Records found
|
|
Page 7 of 7 |
|
|
0.12 (1.04%) 
